Class / Patent application number | Description | Number of patent applications / Date published |
514031000 | The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.) | 59 |
20080207537 | Topical Ungual Formulations - Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail. | 08-28-2008 |
20080261900 | Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections Caused by Antibacterial Drug-Resistant Bacteria - Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions. | 10-23-2008 |
20090036389 | Polymeric Micelle Formulations of Hydrophobic Compounds and Methods - Provided are cosolvent evaporation methods and compositions for improving the solubility of hydrophobic compounds, including therapeutic agents such as anticancer drugs, polyene antibiotics, antilipidemic agents, and hydrophobic compounds used in various industries, and/or for reducing the toxicity of certain hydrophobic therapeutic agents, especially polyene antibiotics, in particular, Amphotericin B (AmB), and therapeutics such as paclitaxel, tamoxifen, an acylated prodrug or an acylated cis-platin, by incorporating these agents within micelles comprising an amphiphilic block-forming copolymer. | 02-05-2009 |
20090156514 | NOVEL MACROLACTAM COMPOUNDS - The invention relates generally to novel macrolactams and their analogs, to processes for the preparation of these novel macrolactams, to pharmaceutical compositions comprising the novel macrolactams; and to methods of using the novel macrolactams to treat or inhibit various disorders. | 06-18-2009 |
20090186838 | Amphotericin Derivatives - The present invention provides new polyene macrolide derivatives which show very low toxicity while retaining high antifungal activity as compared with amphotericin B (AmB). These polyene macrolide derivatives comprise a polyene macrolide backbone having at least one free amino group, wherein the amino group is doubly alkylated with at least one hydrocarbon group carrying a total of at least two basic groups. | 07-23-2009 |
20090221520 | Polyene Antibiotics, Compositions Containing Said Antibiotics, Method and Micro-Organisms Used to Obtain Same and Applications Thereof - The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C | 09-03-2009 |
20100190735 | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis - An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; and, d) at least one anti-fungal antibiotic agent. A stable nystatin containing formulation is also provided comprising a buffering agent, a preservative, a chelating agent and an anti-oxidant. | 07-29-2010 |
20100204168 | Stable needle-shaped crystals of natamycin - The present invention describes natamycin comprising needle shaped crystals. | 08-12-2010 |
20100210575 | STRUCTURING EFFECT OF CHOLESTEROL IN PEG-PHOSPHOLIPID MICELLES, DRUG DELIVERY OF AMPHOTERICIN B, AND COMBINATION ANTIFUNGALS - The disclosure herein relates to embodiments of compositions and methods in connection with polymeric micelles including PEG-phospholipids. Embodiments also relate to the controlled release of pharmaceutical agents in the context of drug delivery. Further disclosed are embodiments of PEG-DSPE/Cholesterol micelle formulations prepared with an antifungal agent, Amphotericin B, with capabilities including slow release of the agent in a deaggregated state. In embodiments, micellar preparations with Amphotericin B are compatible with solubility in aqueous salt solutions, thus allowing for concurrent co-administration of other pharmaceutical agents and/or sodium supplementation. In embodiments, polymeric micelle compositions are employed in combination antifungal therapeutic approaches such as Amphotericin B and other antifungal agents. Also disclosed herein are compositions and methods relating to combinations including AmB:PEG-DSPE, rapamycin:PEG-DSPE, and/or 5-fluorocytosine. | 08-19-2010 |
20100210576 | POLYENE DIESTER ANTIBIOTICS - The present invention discloses a new polyene diester and its preparation. This polyene diester has a structure of Formula 1, which is used as prodrugs by introducing diester group to polyene antibiotics, and these prodrugs exhibit antifungal or antiviral activities through releasing parent polyenes by esterase in vivo. The new derivatives have good antimicrobial activity and better safety. These new derivatives are useful for the antifungal and antiviral treatment. PA-COOR Formula 1 | 08-19-2010 |
20100234313 | STABILIZED MICRONISED PARTICLES - The present invention relates to a method for preparing a suspension of micronised particles of a solid organic compound, which method comprises subjecting the solid organic compound to size reduction by wet grinding under pH conditions wherein the intrinsic surface charge of the size-reduced organic compound is sufficient to keep the suspension stable. | 09-16-2010 |
20100273728 | Formulations For The Oral Administration of Therapeutic Agents and Related Methods - The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid. | 10-28-2010 |
20100286077 | COMPOUNDS - The present invention provides a compound of formula (I′) which is a nystatin derivative having an additional double bond present between C28 and C29 and which is further modified relative to nystatin at one or more of positions C5, C7, C9, C10, C11, C16 or at the amino group of mycosamine. These compounds are used as anti-fungal agents. | 11-11-2010 |
20100305055 | COMBINATIONS OF POLYENE FUNGICIDE WITH CATIONIC SURFACTANTS - A solid composition comprising a cationic surfactant, such as the ethyl ester of the lauramide of the arginine mono-hydrochloride (LAE) and a polyene fungicide such as natamycin is provided. The solid composition is the basis for providing solutions of natamycin of increased concentration. The solid composition may be used for providing a dispersion of natamycin in a suitable liquid, such as tap water or an organic solvent. The dispersion may be further diluted with water. This leads to a solution of natamycin in water. The combination of the cationic surfactant and the polyene fungicide displays a biological effect which is stronger than the effect of each of the two components alone. | 12-02-2010 |
20100305056 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE - Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. Compounds of formula I of the invention are capable of treating and/or preventing the above-identified diseases: | 12-02-2010 |
20110021450 | MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXAZINE COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTOZOAL DISEASE - Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient. | 01-27-2011 |
20110059914 | Stable needle-shaped crystals of natamycin - Stable needle shaped crystals of natamycin having a mean length of between 0.1 and 20 μm. | 03-10-2011 |
20110152211 | METHODS AND FORMULATIONS FOR REDUCING AMPHOTERICIN B TREATMENT SIDE EFFECTS - A method of ameliorating amphotericin treatment side effects in a mammal that comprises administering a therapeutically effective amount of a formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B compound is present, in terms of polyene content, in an amount greater than 90%, and non-amphotericin B polyene compounds are present in an amount of no greater than 10%, and a pharmaceutically effective carrier; and administering a therapeutically effective amount of said formulation to a subject in need thereof. | 06-23-2011 |
20110172175 | PROCESS AND COMPOSITION FOR COATING PROPAGATION MATERIAL - The present invention provides a process for coating a plant propagation material, including a seed, comprising: a.) providing a propagation material, such as seed, to be coated; b.) applying to the propagation material a composition comprising at least one reactant having reactive functionality and, optionally, at least one active ingredient; and c.) polymerising, crosslinking, curing or otherwise reacting the reactant having reactive functionality on the surface of the plant propagation material to form a coating thereon which may encompass an a.i., when present. The present invention further provides a method for enhancing the safety, quality and/or viability of a plant propagation material, including a seed, comprising providing a coated material having less dust-off. | 07-14-2011 |
20110190232 | INSECTICIDAL COMBINATIONS - A method of controlling or preventing damage to a plant, which comprises applying on the plant or a surrounding area thereof a combination comprising (I) abamectin, and (II) cyflumetofen, in any desired sequence or simultaneously. | 08-04-2011 |
20110251146 | TOPICAL ANTIFUNGAL COMPOSITION - A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition. | 10-13-2011 |
20110251147 | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections - Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site. | 10-13-2011 |
20120015897 | NOVEL FORMULATION FOR TREATING FUNGAL INFECTIONS - A novel formulation for treating fungal infections comprising Cholesterol containing Nanosomal Amphotericin B in a Saline Suspension | 01-19-2012 |
20120035124 | USE OF NIFURATEL TO TREAT INFECTIONS CAUSED BY ATOPOBIUM SPECIES - The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat' infections caused by | 02-09-2012 |
20120035125 | FULVIC ACID IN COMBINATION WITH FLUCONAZOLE OR AMPHOTERICIN B FOR THE TREATMENT OF FUNGAL INFECTIONS - A combination of fulvic acid or a salt, ester, or derivative thereof and an antifungal compound selected from fluconazole and amphotericin B for use in the treatment or prophylaxis of a disease or condition of the human or animal body is described. The fulvic acid can be CHD-FA. | 02-09-2012 |
20120077767 | MOLECULAR PREDICTORS OF FUNGAL INFECTION - Methods for identifying fungal infection, assays for identifying genomic and protein markers of fungal infection, and methods for diagnosing the fungal infection. In one aspect, the method of identifying fungal infection by proteomic assay involves measuring the protein levels of proteins listed in Table 2A in a peripheral blood cell sample and comparing the determined protein levels to standard protein levels. In another aspect, subjects identified as being infected with fungal infection are treated with anti-fungals. | 03-29-2012 |
20120101053 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES - The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis. | 04-26-2012 |
20120142621 | Purified Ethyl Ester Sophorolipid for the Treatment of Sepsis - A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by | 06-07-2012 |
20120142622 | STAMBOMYCIN AND DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS DRUGS - The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof. | 06-07-2012 |
20120157396 | PYRAZINAMIDE FOR IMMUNOSTIMULATION AND THE TREATMENT OF LEISHMANIASES - Applicants claim the use of a pyrazine compound of formula I: | 06-21-2012 |
20120196822 | Diyne Compositions - A novel class of diyne compounds and diyne salts provided herein are effective and potent Ole1 protein inhibitors, useful for treating fungal pathogens. Compounds, fungicides and methods are provided as novel, potent and broad spectrum anti-fungal agents for treatment against a wide variety of fungal pathogens in humans and animals, and in the agricultural setting. | 08-02-2012 |
20120225834 | OCULAR IONTOPHORESIS OF CHARGED MICELLES CONTAINING BIOACTIVE AGENTS - This invention is related to pharmaceutical compositions consisting of charged micelles containing bioactive agents. The invention is also related to the methods of delivery of charged micelles to the eye of a mammal by iontophoresis. | 09-06-2012 |
20120245115 | 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities - The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin. | 09-27-2012 |
20120270822 | STABILIZED FORMULATION FOR ORAL ADMINISTRATION OF THERAPEUTIC AGENTS AND RELATED METHODS - Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations. | 10-25-2012 |
20120283205 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 11-08-2012 |
20120329742 | USE OF ANTIFUNGAL COMPOSITIONS TO TREAT UPPER GASTROINTESTINAL CONDITIONS - The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms. | 12-27-2012 |
20130123205 | Antifungal and Antiparasitic Polyene Macrolides - In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject. | 05-16-2013 |
20130225517 | Therapeutic Compounds - The invention provides compounds of formula I: | 08-29-2013 |
20130244962 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES - Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. | 09-19-2013 |
20130252916 | ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM - This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation. | 09-26-2013 |
20130274216 | TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE - The present invention relates to ophthalmic compositions comprising inhibitors of spleen tyrosine kinase (syk). The compositions are particularly well suited for the treatment of ophthalmic infection such as fungal keratitis. The compositions optionally comprise an antiinfective compound such as an antibacterial or antifungal compound. The present invention also relates to methods for treating fungal keratitis using compositions comprising syk inhibitors. | 10-17-2013 |
20130324488 | NEW ANTIFUNGAL COMPOSITIONS - The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. | 12-05-2013 |
20130324489 | NEW ANTIFUNGAL COMPOSITIONS - The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. | 12-05-2013 |
20140155341 | USE OF SS'-DIMETHYL-GLIOTOXIN AS DIAGNOSTIC MARKER OF PATHOLOGIES CAUSED BY GLIOTOXIN-PRODUCING FUNGI OR THEIR DERIVATIVES - The present invention relates to an in vitro method of diagnosis, prognosis and/or monitoring of pathologies caused by gliotoxin-producing fungi or their derivatives, characterized in that it is based on the detection of SS′-dimethyl-gliotoxin in a biological sample. Also relates to the use of the SS′-dimethyl-gliotoxin as marker for the diagnosis, prognosis and/or monitoring of pathologies caused by gliotoxin-producing fungi or their derivatives in a subject. | 06-05-2014 |
20140256663 | Amphotericin Analogous Compounds and Pharmaceutical Compositions Containing Them - The present invention relates to polyene macrolide derivatives according to the formula: | 09-11-2014 |
20140274926 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of Formula I: | 09-18-2014 |
20140303105 | Primycin and components thereof for use in the treatment or prevention of infections caused by specific pathogens - The invention refers to primycin or a primycin component or a combination of primycin components, for use in the treatment or prevention of infections caused by Gram-positive bacteria resistant to methicillin and/or vancomycin and/or mupirocin or by penicillin-resistant streptococci. The invention also covers antibiotic compositions containing these active agents. | 10-09-2014 |
20140364385 | FORAZOLINES, COMPOSITIONS THEREOF AND USES THEREOF - An isolated compound of Formula I and salts thereof are provided: | 12-11-2014 |
20150038441 | KIT-IN-PARTS FOR CLEANING AND TREATING EARS OF COMPANION ANIMALS - The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal. | 02-05-2015 |
20150038442 | POLYELECTROLYTE COMPLEXES COMPRISING NATAMYCINE AND/OR PHOSPHITE FOR BIOCIDE ENHANCEMENT - The invention relates to a composition comprising a polyelectrolyte complex of a polyanion and a polycation, further comprising at least one biocide comprising natamycin and/or phosphite. A preferred composition comprises lignosulfonate and chitosan, preferably in relative amount of from 1:2 to 60:1 (w/w). The invention further relates to methods for generating a composition according to the invention, and to uses of a mixture according to the invention for protecting an agricultural plant or plant part against a pathogen. | 02-05-2015 |
20150045316 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 - The invention provides semisynthetic derivatives of Nystatin A | 02-12-2015 |
20150119349 | NEW ANTIFUNGAL COMPOSITIONS - The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. | 04-30-2015 |
20150126467 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE EFFECTS OF ANTIFUNGAL AGENTS - The disclosure relates to use of alginate oligomers to enhance the effects of antifungal agents. The invention provides a method to improve the efficacy of an antifungal agent against a fungus, said method comprising using said antifungal agent together with an alginate oligomer. The fungus may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antifungal agent in treating a subject infected, suspected to be infected, or at risk of infection, with a fungus. In another aspect the method can be used to combat fungal contamination of a site e.g., for disinfection and cleaning purposes. | 05-07-2015 |
20150291648 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION - The invention provides semisynthetic N-substituted derivatives of the antifungal antibiotic Amphotericin B and water soluble salts and complexes, pharmaceutical compositions and plant and building treatment products comprising the derivatives and their use as antifungal antibiotics. | 10-15-2015 |
20160030388 | DITERPENOID MEMBRANOLIDE COMPOUNDS HAVING ANTI-LEISHMANIA ACTIVITY AND USES THEREOF - In a screening program, the Antarctic sponge | 02-04-2016 |
20160120844 | COMPOSITIONS AND METHODS FOR INHIBITING LEISHMANIA - Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts. | 05-05-2016 |
20160129026 | ANTIFUNGAL AND ANTIPARASITIC POLYENE MACROLIDES - In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject. | 05-12-2016 |
20160151326 | Dronedarone for use in Leishmaniasis, Formulations and Associations for Use in Leishmaniasis | 06-02-2016 |
20160194715 | MOLECULAR PREDICTORS OF FUNGAL INFECTION | 07-07-2016 |